With the rapid development of new drug development, advanced therapies, and innovative medical technologies, regulatory science has become a key field linking scientific innovation, clinical application, and public policy. Regulatory science in the context of medical products emphasizes the use of scientific evidence to support decision-making across the entire lifecycle of medical products—from research and development, regulatory review, to post-marketing management—while responding to the regulatory and societal challenges brought about by healthcare innovation.
The Master’s Degree Program in Regulatory Science for Medicine at the School of Pharmacy, College of Medicine, National Taiwan University (hereinafter referred to as “the Program”) is an interdisciplinary master’s program centered on regulatory science. The Program integrates expertise from science, law, public health, and policy, aiming to cultivate students’ understanding of international regulatory trends and to equip them with the ability to participate in regulatory development, decision-making, and practical implementation based on scientific evidence. The Program places particular emphasis on new drug development, advanced therapies (such as cell and gene therapies), and the development of artificial intelligence (AI)-assisted pharmaceuticals and medical devices. With a balanced focus on both theory and practice, the Program seeks to cultivate high-level professionals capable of making impactful contributions in academia, industry, and government.